|Aethlon Medical -- USA Stock|| |
USD 1.29 0.04 3.01%
Chief Science Officer and VP
Dr. Richard H. Tullis Ph.D. is Chief Science Officer of the Company. He was Vice President Director of Aethlon Medical Inc. Dr. Tullis has extensive biotechnology management and research experience and is the founder of Syngen Research formerly a wholly owned subsidiary of Aethlon Medical Inc. Previously Dr. Tullis cofounded Molecular Biosystems Inc. a former NYSE company. At Molecular Biosystems Dr. Tullis was Director of Oligonucleotide Hybridization Senior Research Scientist and Member of the Board of Directors. In research Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxyhosphorochloridites. Dr. Tullis also codeveloped the first applications of covalently coupled DNAenzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985 Dr. Tullis founded and served as President and CEO of Synthetic Genetics Inc. a pioneer in custom DNA synthesis which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interimCEO of Genetic Vectors Inc. which completed its IPO under his management and was cofounder of DNA Sciences Inc. a company that was eventually acquired by Genetic Vectors
Age: 69 VP Since 2015 Ph.D
Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive postdoctoral work at UCSD, USC, and the University of Hawaii.
The company has return on total asset (ROA)
of (96.79) %
which means that it has lost $96.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (263.52) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 810.87 K in liabilities with Debt to Equity (D/E) ratio of 17.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aethlon Medical has Current Ratio of 16.39 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company was founded in 1991 and is based in San Diego, California. Aethlon Medical operates under Medical Appliances Equipment classification in USA and traded on Nasdaq Capital Markets. It employs 7 people.Aethlon Medical (AEMD) is traded on Nasdaq Capital Markets in USA. It is located in CALIFORNIA, U.S.A and employs 7 people. Aethlon Medical is listed under Measuring and Control Equipment category by Fama And French industry classification.
Aethlon Medical Leadership Team
|John Marco, Executive|
|Sabrina Johnson, Director|
|James Joyce, Chairman|
|Franklyn Barry, Director|
|Rodney Kenley, Director|
|Edward Broenniman, Director|
|Charles Fisher, Director|
|James Frakes, CFO, MBA|
|Richard Tullis, VP, Ph.D|
|Chetan Shah, Director, Ph.D|
Stock Performance Indicators
Most of Macroaxis users are presently bullish on Aethlon Medical. What is your sentiment towards investing in Aethlon Medical? Are you bullish or bearish?
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1)
For any level of risk, select the one which has the highest expected return. 2)
For any expected return, select the one which has the lowest volatility.